Exhibit 99.1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 18, 2015
CANNAPHARMARX, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware |
000-27055 |
24-4635140 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
One Collins Drive, Carneys Point, NJ 08069
(Address of principal executive offices)
856-376-0500
(Registrant's Telephone Number, Including Area Code)
___________________________________________________________________
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On December 18, 2015 a majority of the Board of Directors voted to terminate Christopher P. Schnittker as Chief Financial Officer of the Company. Mr. Schnittker's termination as Chief Financial Officer was effective on December 18, 2015.
Effective December 30, 2015, Gerald E. Crocker resigned as a Director and Chief Executive Officer of CannaPharmaRx, Inc. (the "Company"). A copy of Mr. Crocker's resignation is attached to this Report as Exhibit 99.1.
Effective December 31, 2015, Dr. Alex Giaquinto, PhD resigned as a Director of CannaPharmaRx, Inc. A copy of Mr. Crocker's resignation is attached to this Report as Exhibit 99.2.
On December 18, 2015, James Smeeding was appointed interim President of the Company. Mr. Smeeding's biography is as follows:
JAMES SMEEDING, AGE 65
Interim President
Mr. Smeeding, RPh, MBA, EVP of Professional Services for CannaPharmaRX, is also the executive director of the National Association of Specialty Pharmacy (NASP) as well as the National Association of Cannabis Pharmacy (NACP). His pharmacy degree is from the University of Buffalo and his MBA from the University of Texas. Over the past 40 years his practice orientation has been in hospital pharmacy, clinical services design, home infusion therapy, managed care services, disease management and specialty pharmacy. He is a skilled corporate pharmaceutical executive having developed and led 5 successful companies through initial funding to sale.
Mr. Smeeding's private clients constitute the spectrum of pharmaceutical companies, medical device companies, diagnostic testing and all classes of pharmacy affairs -hospital, retail, chain, managed care, academic and research. His broad expertise in professional affairs has allowed his clients to understand, approach and impact medical and pharmacy affairs from product selection through to the value proposition as well as professional communications, patient communications and safety. He is broadly published and an invited presenter at many national and international conferences. Jim is widely known for his broad interests and his ability to moderate a program to bring out cogent learning points and make the educational program applicable to practice.
-2-
On December 18, 2015, Mathew Sherwood, Vice President of Product Development, was appointed Secretary of the Company. Mr. Sherwood's biography is as follows:
MATHEW SHERWOOD, AGE 38
Vice President; Product Development, Secretary
Mr. Sherwood has more than 20 years of experience in healthcare, both in private practice and as a consultant. Mr. Sherwood worked as a board-certified optician as well as a consultant in both practice management and optical laboratory solutions. As an optician, Mr. Sherwood developed solutions for ophthalmic lens manufacturing and high-performance prescription applications. For most of the last decade, Mr. Sherwood has turned his focus to medical cannabinoid solutions, developing a variety of cannabinoid-based solutions, and has a deep understanding of the potential of cannabinoid products. Mr. Sherwood specializes in extraction technologies and the design and manufacturing of novel delivery systems.
SECTION 9 - FINANCIAL STATEMENTS, PRO FORMA FINANCIALS & EXHIBITS
Item 9.01 Exhibits
(d)
|
Exhibit Number |
Description |
|
99.1 |
Resignation Letter of Gerald E. Crocker |
|
99.2 |
Resignation Letter of Dr. Alex Giaquinto, PhD |
-3-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CANNAPHARMARX, Inc.
By: /s/ James Smeeding
____________________________________
James Smeeding
Title: Interim President
Date: January 12, 2016
-4-
Exhibit 99.1
